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Abstract 
Review on myeloid proliferations related to Down 
syndrome, with data on clinics, pathology, and 
involved genes. 
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Identity 
Other names 
Myeloid proliferations related to Down syndrome: 
transient abnormal myelopoiesis and myeloid 
leukemia associated with Down syndrome 
Transient abnormal myelopoiesis was previously 
known as "transient myeloproliferative disorder" 
and "transient leukemia". 
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Figure 1:  Natural history of transient abnormal myelopoiesis (TAM) and myeloid leukemia of Down syndrome 
(ML-DS) with approximate incidences of those affected. Both trisomy 21 and a somatic GATA1 mutation are 
required for progression to TAM. Most infants with TAM demonstrate extinction of the GATA1 clone; however, 
a subset acquires additional genetic mutations, allowing the progression to ML-DS. Overall, approximately 0.5-
3% of Down syndrome patients develop ML-DS. Figure adapted from Bhatnagar et al., 2016 and Mateos et al., 
2015. 
Clinics and pathology 
Note 
While this review focuses on myeloid proliferations 
in Down syndrome, it should be noted that children 
with Down syndrome are also at an increased risk of 
acute lymphoblastic leukemia (ALL), predominantly 
B lymphoblastic leukemia.  The incidence of ALL in 
Down syndrome children younger than 5 years is 
40.7 times higher compared to non-Down syndrome 
patients of the same age (Hasle et al., 2000).  These 
Down syndrome-associated B-ALL have similar 
clinical features and cytogenetic abnormalities to B-
ALL not associated with Down syndrome, though 
many more B-ALL associated with Down syndrome 
had normal karyotypes, except for their 
constitutional trisomy 21 (Forestier et al., 2008; 
Buitenkamp et al., 2014).  However, these 
lymphoblastic leukemias are more frequently found 
to have overexpression of CRLF2, IKZF1 deletions, 
and/or JAK2 -activating mutations (Hertzberg et al., 
2010; reviewed in Maloney et al., 2015).  Down 
syndrome-associated ALL has a worse prognosis 
and overall event-free survival compared to non-
Down syndrome-associated ALL due to increased 
treatment-related mortality and a higher relapse rate 
(Buitenkamp et al., 2014; reviewed in Maloney et al., 
2015). 
Disease 
Transient abnormal myelopoiesis 
Transient abnormal myelopoiesis (TAM) is 
restricted to newborns with trisomy 21 or those with 
trisomy 21 mosaicism.  The disease is characterized 
by increased peripheral blood blasts, usually 
megakaryoblasts, with or without clinical symptoms.  
Underlying genetics demonstrate somatic mutations 
in the GATA1 gene.  Most cases spontaneously 
resolve within months without any therapeutic 
intervention. 
Phenotype/cell stem origin 
The cell of origin is thought to be the fetal liver 
hematopoietic stem cell/progenitor cell. 
Etiology 
The current hypothesis is that TAM arises in the 
liver.  Evidence supporting this hypothesis includes 
the spontaneous resolution of hematopoiesis in the 
fetal liver within months of birth as hematopoiesis 
fully switches to the bone marrow, which is similar 
to the time course of TAM.  In addition, severe TAM 
demonstrates increased blast infiltration of the liver 
with relative sparing of the bone marrow.  Lastly, 
transgenic mice expressing GATA1 mutations show 
altered megakaryocyte lineage 
proliferation/differentiation only in fetal liver 
progenitors (reviewed in Roy et al., 2009). Evidence 
demonstrates that the presence of trisomy 21 
promotes abnormal megakaryocyte-erythroid 
proliferation in the fetal liver (Chou et al., 2008; 
Tunstall-Pedoe et al., 2008).  The addition of a 
somatic GATA1 mutation transforms the 
progenitors, leading to TAM.  The combination of 
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constitutional trisomy 21 with somatic GATA1 
mutations has been found to be both necessary and 
sufficient for TAM (Nikolaev et al., 2013). 
Epidemiology 
As stated previously, TAM is restricted to newborns 
with trisomy 21, which has an incidence of 
approximately 1/700 live births.  Clinical TAM (i.e. 
those with obviously increased blasts with or without 
symptoms) occurs in approximately 4-10% of those 
with trisomy 21.  Approximately 5-16% of those 
affected with TAM have trisomy 21 mosaicism 
(Klusmann et al., 2008; Gamis et al., 2011).  GATA1 
mutations have been identified in 3.8% up to 30% of 
neonates with Down syndrome (Pine SR et al., 2007; 
Roberts et al., 2013).  In a recent study using targeted 
next-generation sequencing of all Down syndrome 
neonates, low abundance GATA1 mutant clones 
were detected in 20.4% of neonates who were 
originally negative for mutations by Sanger 
sequencing/denaturing high performance liquid 
chromatography and thought to not have TAM 
(Roberts et al., 2013); the disease associated with 
these low level GATA1 mutation clones has been 
termed "silent TAM" due to their indistinguishable 
clinical picture and laboratory values compared to 
Down syndrome infants without TAM, including 
<10% blasts. 
Clinics 
The clinical presentation of TAM is variable, with 
many infants (10-25%) being asymptomatic, only 
presenting with increased circulating blasts (Massey 
et al., 2006; Klusmann et al., 2008).  While there is 
no defined percentage of blasts for the diagnosis of 
TAM, a threshold of >10% blasts has recently been 
found to have 100% sensitivity for detecting  a 
coexisting GATA1 mutation, though the specificity 
is only 74% (Roberts et al., 2013).  This specificity 
is low because, in general, Down syndrome neonates 
have increased peripheral blood blasts (median 4%; 
Roberts et al., 2013).  Others recommend a blast 
minimum percentage of 20% (reviewed in Roberts 
and Izraeli, 2014).  Of note, those with "silent TAM" 
do not have increased blasts compared to Down 
syndrome neonates without TAM.  
 
The median presentation is within 3-7 days of birth.  
There is a slight male predominance with a 
male:female ratio of 1.2-1.5:1 (Massey et al., 2006; 
Klusmann et al., 2008).  Peripheral blood evaluation 
also usually demonstrates a leukocytosis and an 
abnormal platelet count (usually thrombocytopenia, 
but thrombocytosis has also been identified); 
hemoglobin and absolute neutrophil counts are 
usually within normal limits.  Of note, Down 
syndrome neonates without a diagnosis of clinical or 
silent TAM also often have similar peripheral blood 
abnormalities, so no individual finding other than 
increased blasts >10% is sensitive for a diagnosis of 
clinical TAM. 
 
The most common clinical symptom is 
hepatomegaly, which is a result of megakaryoblast 
infiltration and/or hepatic fibrosis.  This fibrosis is 
thought to be due to overexpression of platelet-
derived growth factor and transforming growth 
factor-β ( TGFB1)by megakaryoblasts, and portends 
a poor prognosis (Klusmann et al., 2008).    Other 
clinical findings include splenomegaly, exudative 
effusions (including pleural, pericardial, and 
ascites), and respiratory distress (due to 
hepatomegaly). Clinically severe TAM including 
these aforementioned symptoms occurs in 
approximately 10-30% of patients with clinically 
diagnosed TAM (reviewed in Roberts and Izraeli, 
2014).  In utero presentations include hydrops fetalis 
and anemia. 
 
Figure 2:  Peripheral blood smear reveals increased blasts which are medium to large in size with smooth 
chromatin, prominent nucleoli (sometimes multiple) and basophilic cytoplasm.  Some of these blasts may 
demonstrate cytoplasmic blebs.  Giant platelets may often be seen. 
Cytology 
Blasts are characterized as medium to large cells 
with high nuclear-to-cytoplasmic ratios, smooth 
chromatin, prominent nucleoli, and deeply 
basophilic cytoplasm, often with cytoplasmic blebs.  
Cytoplasmic azurophilic granules may be identified. 
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Pathology 
Usually a bone marrow aspirate and/or biopsy does 
not need to be performed as the peripheral blood 
blast count is equal to or exceeds the bone marrow 
blast percentage.  If performed, the bone marrow 
may demonstrate variable numbers of 
megakaryocytes, including frequent dysplastic 
forms such as micromegakaryocytes.  Variable 
numbers of blasts may be present, in one study 
ranging from 0-87%, with a mean of 26% (Massey 
et al., 2006).  Dyserythropoiesis may be seen in up 
to 25% of patients (Massey et al., 2006).  Liver 
biopsies may demonstrate fibrosis with sinusoidal 
infiltration by megakaryoblasts (Massey et al., 
2006). 
 
Figure 3:  Bone marrow biopsy from a patient with TAM demonstrates increased blasts characterized as large 
cells with round to irregular nuclear contours, prominent nuclei, and mild amounts of cytoplasm.  Background 
maturing erythroid and myeloid precursors are identified. 
Cytogenetics 
Cytogenetics performed on peripheral blood most 
often demonstrates only trisomy 21 (Massey et al., 
2006).  However, approximately 20% of affected 
infants have additional cytogenetic aberrations 
including MLL gene rearrangements and complex 
karyotypes (Klusmann et al., 2008). 
Genes 
TAM is characterized by somatic mutations in the 
transcription factor gene GATA1 on chromosome 
Xp11.23.  These mutations are predominantly within 
exon 2 (97%), with the remaining identified mostly 
in exon 3.1 (Alford et al., 2011).  GATA1 mutations 
result in N-terminal truncating mutations leading to 
a shortened GATA1 protein, GATA1s.  Of note, 10-
20% of cases of TAM have multiple GATA1 mutant 
clones (Alford et al., 2011; Roberts et al., 2013).  
Whole exome sequencing of TAM cases has reveal 
low numbers of non-silent mutations in other genes 
in these patients (1.7, range 1-5; Yoshida et al., 
2013).  However, Nikolaev et al. (2013) found that 
the presence of such additional mutations can 
accumulate in TAM without immediate progression 
to ML-DS, and that these individuals with additional 
mutations can still have disease regression. 
Treatment 
Approximately 66-84% of infants will have 
spontaneous resolution of their blasts and symptoms 
without a need for intervention (Klusmann et al., 
2008; Gamis et al., 2011).  The remaining infants 
may need supportive therapy or chemotherapy.  In 
previous trials, supportive care measures including 
exchange transfusions and/or leukapheresis were 
provided for hyperviscosity, blast counts >100K/uL, 
organomegaly with respiratory compromise, heart 
failure, hydrops fetalis, liver dysfunction, and 
disseminated intravascular coagulation (DIC) 
(Gamis et al., 2011).  Even more severe life-
threatening symptoms have been treated 
successfully with cytarabine (cytosine arabinose), to 
which the blasts are highly sensitive (Massey et al., 
2006). 
Evolution 
The majority of patients (66-84%) have spontaneous 
resolution of clinical and laboratory abnormalities 
without treatment within 2-3 months (Klusmann et 
al., 2008).  Peripheral blasts usually clear prior to 
hepatomegaly resolution (Gamis et al., 2011).  
Approximately 16-30% of infants, whether they 
were asymptomatic or had clinical symptoms, 
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develop myeloid leukemia of Down syndrome 
(Klusmann et al., 2008) (see below). 
Prognosis 
While most infants have spontaneous resolution, 
approximately 15-20% of infants still die; however, 
approximately half of these deaths are not TAM-
related, but instead related to other congenital 
abnormalities of trisomy 21 (Klusmann et al., 2008; 
Gamis et al., 2011).  TAM mortality risk factors 
include WBC >100 K/uL, prematurity, ascites, 
effusions, bleeding diathesis/ coagulopathy, and 
failure to spontaneously clear peripheral blasts 
(Klusmann et al., 2008).  Those with pathologically 
diagnosed hepatic fibrosis are more likely to die of 
disease (Gamis et al., 2011). 
Disease 
Myeloid leukemia of Down syndrome 
Note 
Myeloid leukemia of Down syndrome (ML-DS) 
encompasses a spectrum of myelodysplastic 
syndrome and its evolution into leukemia in children 
with Down syndrome. 
Etiology 
Similar to TAM, trisomy 21 and a somatic GATA1 
mutation are thought to be required for the 
development of ML-DS. However, for this 
progression, additional genetic and/or epigenetic 
events are required. Children over 5 years old may 
not have mutations in the GATA1 gene, and possible 
consideration should be given to a more 
conventional MDS or AML similar to those 
diagnosed in non-Down syndrome patients; these 
children may need therapy with appropriate non-
Down syndrome protocols. 
In those under 5 years of age, most cases of ML-DS 
(~70%) are acute megakaryoblastic leukemia (AML 
M7 by French-American-British (FAB) 
categorization) (Gamis et al, 2003). Occasional 
presentations of FAB M0, M1, M2, and M4/M5 have 
also been reported (Lange et al., 1998; Rao et al., 
2006). 
Epidemiology 
The incidence of acute myeloid leukemia in 
individuals with Down syndrome is 0.5-3%, up to 
150 times greater than that in individuals without 
Down syndrome of the same age; the incidence of 
acute megakaryoblastic leukemia in individuals with 
Down syndrome is up to 500 times greater than that 
in individuals without Down syndrome (Creutzig et 
al., 1996; Hasle et al., 2000). ML-DS usually 
presents between 1-4 years of age (median 1.5 years) 
(Klusmann et al., 2008). This disease develops in 
approximately 16-30% of children with a clinical 
history of TAM. However, when taking into account 
those with "silent TAM", the risk of developing ML-
DS is approximately 5-11% (Roberts et al., 2013). At 
this time, there are no specific clinical, laboratory, or 
molecular features that predict the risk of TAM 
transforming into ML-DS. Similarly, whether an 
individual receives treatment for TAM has not been 
correlated with the progression to ML-DS. 
Of note, GATA1 gene mutation testing/monitoring 
is not currently the standard of care in patients with 
Down syndrome. Many groups advocate for a 
peripheral blood smear with differential at birth and 
every three months thereafter until the age of 4 years, 
at which time the risk of leukemia is reduced (Roy et 
al., 2009; Mateos et al., 2015; Bhatnagar et al., 
2016). 
Clinics 
ML-DS may occur after a remission time period 
from TAM, or as an overt progression/evolution of 
TAM without a period of remission. In the latter, the 
infant may have persistent abnormal laboratory 
values over several months, and in the former, the 
laboratory values tend to normalize. In those with 
silent TAM or in remission, ML-DS is usually first 
detected by thrombocytopenia with or without 
leukopenia and anemia and with low numbers or 
absent circulating blasts (Lange et al., 1998). In 
approximately 70% of patients, myelodysplastic 
syndrome precedes acute leukemia (Creutzig et al., 
1996). Hepatosplenomegaly may be present. 
Compared to non-Down syndrome cases of myeloid 
leukemia, ML-DS cases are less likely to have 
lymphadenopathy and CNS blast involvement 
(Gamis et al., 2003). 
Cytology 
Peripheral blood and bone marrow blasts in ML-DS 
are similar to those in TAM, both morphologically 
and immunophenotypically. The bone marrow 
aspirate may be hemodilute and/or aparticulate due 
to marrow fibrosis hampering aspiration. During the 
myelodysplastic syndrome phase, dysplastic 
changes of megakaryocytes and erythroid cells may 
also be identified along with low levels of blasts in 
the bone marrow. 
Pathology 
A bone marrow biopsy usually demonstrates 
progressive fibrosis. Blasts and dysplastic 
megakaryocytes are the predominant cells. The 
blasts have a similar immunophenotype to those in 
TAM, expressing CD34, CD117, CD13, CD33, 
CD36, CD71, variable CD41, variable CD42b, 
variable CD61, CD56, dim CD4, and aberrant 
expression of CD7 (Gamis et al., 2003); however, 
approximately 50% of cases do not express CD34, 
and 30% of cases do not express CD56 and CD41. 
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Figure 4:  Increased blasts may be identified on a bone marrow aspirate if it does contain particles. These blasts 
are characterized as medium to large sized cells with round to irregular nuclear contours, smooth chromatin, 
prominent nucleoli (sometimes multiple), and basophilic cytoplasm often with cytoplasmic blebs. Rare blasts 
may demonstrate cytoplasmic granules such as the blast in the bottom center. Dysplastic megakaryocytes may 
also be identified such as the small megakaryocyte at the top center. 
 
 
Figure 5:  In the bone marrow biopsy obtained from the same patient demonstrated in Figure 4, the core biopsy 
demonstrates increased blasts with prominent nucleoli in a background of maturing erythroid and myeloid 
precursors. 
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Figure 6:  Other bone marrow biopsies may demonstrate marked fibrosis, as demonstrated by the bottom panel 
stained for reticulin. The core biopsy can demonstrate a marked increase in atypical and dysplastic 
megakaryocytes, many of which are blasts. The inset panel demonstrates CD117 immunohistochemical staining 
of the megakaryoblasts. 
 
Cytogenetics 
Karyotypes in ML-DS often demonstrate only the 
constitutional trisomy 21 (25-29% of cases) (Lange 
et al., 1998; Blink et al., 2014). Recurrent genetic 
abnormalities such as t(8;21), t(15;17), and inv(16) 
are underrepresented in this cohort compared to 
those without Down syndrome. The translocation 
t(1;22) often found in infant megakaryoblastic 
leukemia is only rarely found in ML-DS. However, 
trisomy 8 is a common cytogenetic abnormality, 
occurring in 13-36% of patients, as is an additional 
nonconstitutional chromosome 21 (Creutzig et al., 
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1996; Lange et al., 1998; Gamis et al., 2003; Blink 
et al., 2014). Loss of chromosome 5 and/or loss of 
chromosome 7 material is present in 23% of cases 
(Blink et al., 2014). 
Genes 
N-terminal somatic mutations in the GATA1 gene 
are present in all cases of ML-DS, and, usually, an 
individual has the same GATA1 clone in both TAM 
and ML-DS. However, 10-20% of cases of TAM 
have multiple GATA1 mutant clones, and the larger 
size of the GATA1 mutant clone has not been found 
to always correspond with the clone present in ML-
DS (Nikolaev et al., 2013; Yoshida et al., 2013). By 
whole exome sequencing, more non-silent mutations 
in additional genes are present in ML-DS compared 
to TAM, with recurrent mutations identified in core 
cohesion components (including RAD21 and 
STAG2), CTCF, epigenetic regulators (including 
EZH2 and KANSL1), RAS pathway genes 
(including NRAS, JAK1, and JAK2), and other 
genes (including DCAF7 and TP53) (Yoshida et al., 
2013). 
Treatment 
Unlike TAM, ML-DS does require chemotherapy to 
achieve complete remission (CR). However, 
compared to non-Down syndrome pediatric acute 
leukemia, they can be treated with reduced intensity 
chemotherapy protocols without stem cell 
transplantation. Reduced chemotherapy intensity is 
encouraged due to high rates of treatment toxicity in 
Down syndrome children (Lange et al., 1998). 
Prognosis 
Unlike non-Down syndrome myeloid leukemia, ML-
DS has a better prognosis, with better induction 
remission rates and reduced relapse rates (Lange et 
al., 1998; Gamis et al., 2003; Rao et al., 2006). Blink 
et al. (2014) reported a 7-year event-free and overall 
survival rate of 78% and 79%, respectively. 
However, ML-DS children are still at high risk for 
treatment-related deaths, often due to infection 
(Lange et al., 1998; Rao et al., 2006). White blood 
count >20K/uL and age >3 years are independent 
predictors for poor event-free survival (Blink et al., 
2014). In another study, age >2 years was correlated 
with a five fold increase in adverse outcomes (Gamis 
et al., 2003). A normal karyotype (except for the 
constitutional trisomy 21) has also been found to 
independently predict inferior overall survival, 
event-free survival, and relapse-free survival (Blink 
et al., 2014). 
Genes involved and 
proteins 
GATA1 (GATA binding protein 1 
(globin transcription factor1)) 
Location 
Xp11.23 
Protein 
GATA1 protein is a transcription factor which 
regulates megakaryocytes and erythroid 
differentiation. 
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